AI Summary Trikafta, Orkambi, Symdeko, and Kalydeco treat cystic fibrosis in people with eligible CFTR mutations, and none is specifically approved or indicated to treat liver disease.
Medically reviewed.
Cystic fibrosis–associated liver disease (CFLD) is liver disease that can develop in people with cystic fibrosis (CF). CF is linked to mutations in the CFTR gene, which lead to a defective CFTR protein. Treatment on this page centers on CFTR modulators, prescription medicines that improve how the CFTR protein works. They treat CF itself and may also support liver health.
This page introduces four CFTR modulators: Trikafta, Orkambi, Symdeko, and Kalydeco. None is specifically approved or indicated to treat liver disease. You can also connect with a liver specialist to discuss whether one of these therapies fits your care plan.
Liver Health AI Assistant
Ask Aimy
Aimy answers from LiverDirectory’s reviewed health information — helping patients make sense of liver-health terms, prepare for specialist visits, and explore what to look up next.
CFTR MODULATOR OVERVIEW
CFTR modulators are prescription medicines that treat the underlying protein defect in cystic fibrosis. Some help the defective CFTR protein reach the cell surface. Others help it open and work better. Improving the CFTR defect may also support liver health in people with CFLD. Care typically combines medication, routine CF care, and regular monitoring.
The four therapies below are each used to treat cystic fibrosis in people with eligible CFTR mutations. Eligibility depends on genetic testing and your health history, so a liver specialist and your CF care team can help you understand which option fits your care plan.
Trikafta is a combination CFTR modulator for cystic fibrosis in people with eligible CFTR mutations. It improves the processing and trafficking of the defective CFTR protein and increases the amount of working protein at the cell surface.
Explore this therapy:
Orkambi is a combination CFTR modulator for people who have two copies of the F508del CFTR mutation. Lumacaftor helps the CFTR protein get to the cell surface, and ivacaftor helps it work. Orkambi is not specifically indicated to treat CFLD.
Explore this therapy:
Symdeko is a combination CFTR modulator for people with eligible CFTR mutations. It improves the quantity and function of the defective CFTR protein and is used as long-term treatment.
Explore this therapy:
Kalydeco is a CFTR potentiator for people with specific responsive CFTR mutations. Unlike combination modulators, it improves the function of CFTR proteins that are already at the cell surface.
Explore this therapy:
Providers may prescribe a CFTR modulator for people who have cystic fibrosis with an eligible CFTR mutation confirmed by genetic testing. These medicines are used for long-term treatment of CF, including its effects on the lungs. Which medicine fits depends on your specific mutation.
DIET & LIFESTYLE SUPPORT
CFTR modulators work best alongside routine cystic fibrosis care. Nutrition, airway clearance, hydration, and avoiding smoke exposure all support treatment.
Trikafta, Orkambi, Symdeko, and Kalydeco are all taken with fat-containing food, which improves absorption. Adequate nutrition and calories are part of CF care.
Patients are advised to keep up airway clearance therapy and stay hydrated. Routine exercise as tolerated is also recommended.
Avoid smoke exposure and follow your CF infection prevention practices. Your CF care team can tailor these steps to you.
A nutrition bar designed for liver health can be a simple way to support your eating habits alongside medication. Ask your CF care team how it fits your calorie and fat goals.
Explore Liver Health Nutrition Bars
CFTR MODULATORS AND CFLD
CFTR modulators were developed to treat cystic fibrosis, not liver disease. In people with CFLD, improving the underlying CFTR defect may also help support liver health. None of these medicines is specifically approved or indicated to treat CFLD.
Because of this, your providers weigh your cystic fibrosis treatment needs and your liver health together when choosing a plan.
Improving the underlying CFTR defect with Trikafta may also help support liver health in people with CFLD. Trikafta is not specifically approved to treat liver disease.
For Symdeko and Kalydeco, treatment may support liver health in people with CFLD. Neither is specifically indicated to treat liver disease.
Orkambi is not specifically indicated to treat CFLD, even though people with cystic fibrosis may develop liver disease.
These medicines treat the underlying cause of cystic fibrosis rather than only its symptoms. Their main benefits are better lung function, fewer lung flare-ups, and better quality of life. Your healthcare provider can explain how this applies to your liver condition.
TREATMENT MONITORING
Regular monitoring helps your healthcare provider see how your body is responding to CFTR modulator therapy and track changes in your liver over time. Regular liver function tests are recommended for Trikafta, Orkambi, Symdeko, and Kalydeco.
Liver function tests track liver enzymes. Elevated liver enzymes are a listed common side effect of these medicines, so regular testing helps flag changes early.
Your provider also tracks your overall treatment response. For Orkambi, this includes blood pressure and respiratory status.
Eye exams are recommended for children and teens taking these medicines. Dosing may be adjusted in people with liver impairment or who take certain other medicines.
Only a qualified healthcare provider can adjust your treatment plan based on your test results and health history.
COMMON QUESTIONS
CFTR modulator therapy treats the underlying protein defect in cystic fibrosis. It includes Trikafta, Orkambi, Symdeko, and Kalydeco. In people with cystic fibrosis–associated liver disease (CFLD), improving the CFTR defect may also support liver health. None of these medicines is specifically approved or indicated to treat liver disease. Talk with your liver specialist and CF care team about your plan.
They improve how the CFTR protein works. Some, such as the tezacaftor and lumacaftor in Trikafta, Symdeko, and Orkambi, improve the processing and trafficking of the defective protein. Ivacaftor helps the CFTR channel open, which improves the movement of chloride and water across cells. This helps thin mucus and improve lung function. Your provider can explain how this applies to you.
No. Trikafta, Symdeko, and Kalydeco are not specifically approved or indicated to treat liver disease. Orkambi is not specifically indicated to treat CFLD. For people with CFLD, treating the underlying CFTR defect may also support liver health. Ask your provider what to expect for your liver.
Healthcare providers may consider a CFTR modulator for people who have cystic fibrosis with an eligible CFTR mutation. Genetic testing confirms eligibility. Orkambi is for people with two copies of the F508del mutation. Kalydeco is for specific responsive mutations. Only a qualified provider can decide which medicine fits your situation.
Elevated liver enzymes are a listed common side effect of Trikafta, Orkambi, and Kalydeco, so your provider will check your liver function regularly. Other listed side effects for Trikafta and Kalydeco include headache, upper respiratory tract infection, abdominal pain, and diarrhea. Orkambi may also cause shortness of breath (especially when starting), headache, nausea, and diarrhea. Your provider can help manage any side effects.
Yes. Follow-up usually includes regular liver function tests and a review of how well the treatment is working. Children and teens also have eye exams. Monitoring helps your provider spot changes early and adjust your plan if needed. Only your healthcare provider should change your treatment.
No. These medicines work alongside routine CF care, not instead of it. Care includes adequate nutrition, airway clearance therapy, hydration, taking doses with fat-containing food, and avoiding smoke exposure. Ask your CF care team how to build a plan that pairs medication with these habits.
Medical disclaimer: LiverDirectory provides educational information and a directory of providers. It does not provide medical advice, diagnosis, or treatment. Always consult a licensed physician regarding any medical condition.
